SHIM
MBRX icon

Stone House Investment Management’s Moleculin Biotech MBRX Stock Holding History

Stone House Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132
Closed -$996 – 753
2025
Q2 		$996 Buy
+132
New +$2.71K ﹤0.01% 455

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
WDG
Wealth Dimensions Group Cincinnati, Ohio $558M AUM 20.63% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stone House Investment Management's MBRX Position: Q3 2025 in Review

Stone House Investment Management sold out of Moleculin Biotech (MBRX) in Q3 2025, closing a stake of 132 shares — an estimated $996 sold.

Stone House Investment Management first reported a position in MBRX in Q2 2025 and held it in 1 quarter. The position peaked at $996 in Q2 2025. 24 funds tracked by Wall St. Rank hold MBRX as of Q3 2025.

  • Stone House Investment Management reported no remaining Moleculin Biotech position as of Q3 2025 after selling out during the quarter.
  • Stone House Investment Management sold 132 Moleculin Biotech shares in Q3 2025, an estimated $996.
  • Stone House Investment Management first reported a position in Moleculin Biotech in Q2 2025 and held it in 1 quarter.
  • Stone House Investment Management's Moleculin Biotech position peaked at $996 in Q2 2025.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2025.

Based on Stone House Investment Management's 13F filing for Q3 2025, filed 27 Oct 2025.